Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1973 1
1974 1
1976 1
1977 7
1978 8
1979 10
1980 3
1981 5
1982 7
1983 9
1984 14
1985 8
1986 10
1987 8
1988 4
1989 8
1990 8
1991 7
1992 7
1993 8
1994 6
1995 7
1996 12
1997 12
1998 11
1999 10
2000 16
2001 3
2002 12
2003 10
2004 5
2005 10
2006 11
2007 14
2008 12
2009 14
2010 11
2011 10
2012 13
2013 10
2014 7
2015 9
2016 5
2017 9
2018 3
2019 3
2020 4
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

367 results
Results by year
Filters applied: . Clear all
Page 1
Intermittent blockade of OGFr and treatment of autoimmune disorders.
Zagon IS, McLaughlin PJ. Zagon IS, et al. Among authors: mclaughlin pj. Exp Biol Med (Maywood). 2018 Dec;243(17-18):1323-1330. doi: 10.1177/1535370218817746. Epub 2018 Dec 12. Exp Biol Med (Maywood). 2018. PMID: 30541348 Free PMC article. Review.
Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature.
Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szynkiewicz M, Dickerson JE, Bhaskar SS, Zampini M, Briggs TA, Jenkinson EM, Bacino CA, Battini R, Bertini E, Brogan PA, Brueton LA, Carpanelli M, De Laet C, de Lonlay P, del Toro M, Desguerre I, Fazzi E, Garcia-Cazorla A, Heiberg A, Kawaguchi M, Kumar R, Lin JP, Lourenco CM, Male AM, Marques W Jr, Mignot C, Olivieri I, Orcesi S, Prabhakar P, Rasmussen M, Robinson RA, Rozenberg F, Schmidt JL, Steindl K, Tan TY, van der Merwe WG, Vanderver A, Vassallo G, Wakeling EL, Wassmer E, Whittaker E, Livingston JH, Lebon P, Suzuki T, McLaughlin PJ, Keegan LP, O'Connell MA, Lovell SC, Crow YJ. Rice GI, et al. Among authors: mclaughlin pj. Nat Genet. 2012 Nov;44(11):1243-8. doi: 10.1038/ng.2414. Epub 2012 Sep 23. Nat Genet. 2012. PMID: 23001123 Free PMC article.
The RNA-editing enzyme ADAR1 controls innate immune responses to RNA.
Mannion NM, Greenwood SM, Young R, Cox S, Brindle J, Read D, Nellåker C, Vesely C, Ponting CP, McLaughlin PJ, Jantsch MF, Dorin J, Adams IR, Scadden AD, Ohman M, Keegan LP, O'Connell MA. Mannion NM, et al. Among authors: mclaughlin pj. Cell Rep. 2014 Nov 20;9(4):1482-94. doi: 10.1016/j.celrep.2014.10.041. Epub 2014 Nov 13. Cell Rep. 2014. PMID: 25456137 Free PMC article.
[Met5]-enkephalin preserves diffusion metrics in EAE mice.
Patel C, Meadowcroft MD, Zagon IS, McLaughlin PJ. Patel C, et al. Among authors: mclaughlin pj. Brain Res Bull. 2020 Dec;165:246-252. doi: 10.1016/j.brainresbull.2020.10.015. Epub 2020 Oct 24. Brain Res Bull. 2020. PMID: 33141073
Blockade of the OGF-OGFr pathway in diabetic bone.
Titunick MB, Lewis GS, Cain JD, Zagon IS, McLaughlin PJ. Titunick MB, et al. Among authors: mclaughlin pj. Connect Tissue Res. 2019 Nov;60(6):521-529. doi: 10.1080/03008207.2019.1593396. Epub 2019 Mar 31. Connect Tissue Res. 2019. PMID: 30931654
Naltrexone as a Novel Therapeutic for Diabetic Corneal Complications.
McLaughlin PJ, Sassani JW, Zagon IS. McLaughlin PJ, et al. J Cell Immunol. 2020;2(2):42-46. doi: 10.33696/immunology.1.018. J Cell Immunol. 2020. PMID: 32368758 Free PMC article.
Endogenous Opioids in the Etiology and Treatment of Multiple Sclerosis.
Zagon IS, McLaughlin PJ. Zagon IS, et al. Among authors: mclaughlin pj. In: Zagon IS, McLaughlin PJ, editors. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis [Internet]. Brisbane (AU): Codon Publications; 2017 Nov 27. Chapter 8. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. 2017. PMID: 29261263 Free Books & Documents. Review.
Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes.
McLaughlin PJ, Sassani JW, Titunick MB, Zagon IS. McLaughlin PJ, et al. BMC Ophthalmol. 2019 Jan 28;19(1):35. doi: 10.1186/s12886-019-1044-y. BMC Ophthalmol. 2019. PMID: 30691415 Free PMC article.
Duration of opioid receptor blockade determines biotherapeutic response.
McLaughlin PJ, Zagon IS. McLaughlin PJ, et al. Biochem Pharmacol. 2015 Oct 1;97(3):236-46. doi: 10.1016/j.bcp.2015.06.016. Epub 2015 Jun 25. Biochem Pharmacol. 2015. PMID: 26119823 Review.
Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.
Zagon IS, Sassani JW, Purushothaman I, McLaughlin PJ. Zagon IS, et al. Among authors: mclaughlin pj. Exp Biol Med (Maywood). 2020 Nov 17:1535370220972060. doi: 10.1177/1535370220972060. Online ahead of print. Exp Biol Med (Maywood). 2020. PMID: 33203224
367 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback